Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, is enhancing its bioconjugation offering through an agreement with Singzyme, a company focused on developing enzymes for protein ligation.   Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest. The bioconjugation platform enables the development of novel targeted drugs for p...